Media headlines about Arca Biopharma (NASDAQ:ABIO) have trended somewhat negative this week, according to Accern. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Arca Biopharma earned a coverage optimism score of -0.04 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 47.0705858959414 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
ABIO traded down $0.02 during trading on Thursday, hitting $0.51. The stock had a trading volume of 257,838 shares, compared to its average volume of 897,601. Arca Biopharma has a twelve month low of $0.45 and a twelve month high of $2.71.
Arca Biopharma (NASDAQ:ABIO) last announced its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.20).
Arca Biopharma Company Profile
ARCA biopharma, Inc, a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. The company's lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in chronic heart failure patients with reduced left ventricular ejection fraction.
Receive News & Ratings for Arca Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arca Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.